Luis Alberto Menchén Viso-rekin lankidetzan egindako argitalpenak (4)

2019

  1. Anti-tumour necrosis factor discontinuation in inflammatory bowel disease patients in remission: study protocol of a prospective, multicentre, randomized clinical trial

    Therapeutic Advances in Gastroenterology, Vol. 12

2017

  1. Clinical Outcomes of Golimumab as First, Second or Third Anti-TNF Agent in Patients with Moderate-to-Severe Ulcerative Colitis

    Inflammatory Bowel Diseases, Vol. 23, Núm. 8, pp. 1394-1402

2013

  1. Does smoking influence Crohn's disease in the biologic era? the TABACROHN study

    Inflammatory Bowel Diseases, Vol. 19, Núm. 1, pp. 23-29

  2. High smoking cessation rate in Crohn's disease patients after physician advice - The TABACROHN Study

    Journal of Crohn's and Colitis, Vol. 7, Núm. 3, pp. 202-207